BAXTER INVESTS $20 MIL. IN TRANSPLANT TECHNOLOGY JOINT VENTURE WITH DNX
BAXTER INVESTS $20 MIL. IN TRANSPLANT TECHNOLOGY JOINT VENTURE WITH DNX, the companies announced Aug. 30. The new entity, Nextran, will seek to develop and commercialize technologies "to improve the success and increase the availability of organ transplantation." Under the terms of the agreement, Baxter will own 70% of Nextran and Princeton, N.J.-based DNX will hold 30% of the firm. Nextran will operate as an affiliate of Baxter.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth